Fresh analysis reveals that patients who stop using popular weight-loss injections like Mounjaro or Wegovy tend to recover lost weight far faster than those who end traditional diet and exercise plans.
Findings released in a leading medical journal shows that while overweight people frequently drop about a fifth of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing these treatments need to be aware of the danger of fast weight regain when the medication concludes," cautioned expert Dr. Susan Jebb.
This pace of regain implies a reversion to original weight in about a year and a half.
Comparing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of participants, compared the results of GLP-1 agonists with other pills.
The team note that individuals who lose weight through diet and exercise typically see a less rapid creep back—around 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Experts propose the mechanism of the drugs accounts for the heightened regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal might result in the body to produce less of its own natural hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement leads to appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines advise the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
Professionals argue that, due to the high risk of weight regain, the treatment is often ongoing.
This perspective is reinforced by pharmaceutical companies, who state that the findings "highlight the long-term nature of excess weight," similar to managing conditions like diabetes.
User Experiences
Users who have stopped the jabs describe a sudden return of hunger.
"It was like a trigger flipping and you're instantly extremely hungry," recalled one woman.
This challenge is worsened if patients have not established lasting lifestyle or habit modifications during therapy.
Widespread Interest
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is greater among females than males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic fix and long-term success likely depends on ongoing behavioural management.
